Dimerix Limited (DXB.AX) Stock Analysis

DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES

Fri, September 4, 2026 at 11:00 AM UTC 4 min read

Dimerix (DXB.AX) has secured a non-dilutive funding facility of A$34 million to support its key clinical milestones. This funding is significant for investors as it allows the company to advance its clinical programs without diluting existing shareholder equity, potentially enhancing shareholder value and confidence in its growth trajectory. The successful financing underscores Dimerix's commitment to progressing its innovative therapies.

Read full article →

Dimerix acquisition of DMX-652 bolsters kidney disease development

Wed, July 29, 2026 at 3:34 PM UTC 3 min read

Dimerix (DXB.AX) has acquired DMX-652, a promising drug candidate aimed at treating kidney disease. This acquisition enhances Dimerix's pipeline and strengthens its position in the renal therapeutics market, potentially leading to significant revenue opportunities. Investors should view this development as a strategic move that could accelerate growth and improve the company's long-term prospects in a critical healthcare sector.

Read full article →